Literature DB >> 26168957

Transforming growth factor β type II receptor as a marker in diffuse large B cell lymphoma.

Shudan Mao1, Wenqi Yang2, Limei Ai1, Zhe Li1, Jieping Jin3.   

Abstract

The objective of this study was to investigate the expression and significance of the transforming growth factor β type II receptor (TGFβRII) in diffuse large B cell lymphoma. All patients were enrolled at the First Affiliated Hospital of Liaoning Medical University between 2001 and 2007. The median follow-up period was 53.3 months. Of the 338 patients studied, 131 (38.76 %) had TGFβRII positive expression on immunohistochemistry. The 5 year survival rate was significantly higher in patients with TGFβRII expression than in those without TGFβRII expression (40.3 vs. 31.6 %, P = 0.041). Multivariate analysis identified TGFβRII expression as an independent predictive parameter for survival, in addition to lactate dehydrogenase, clinical stage, and histologic subtype. TGFβRII expression may be considered a new prognostic factor of diffuse large B cell lymphoma.

Entities:  

Keywords:  Diffuse large B cell lymphoma; Survival; TGFβRII

Mesh：

Substances：

Year:  2015        PMID： 26168957     DOI： 10.1007/s13277-015-3700-z

Source DB:  PubMed          Journal:  Tumour Biol        ISSN： 1010-4283


  43 in total

1.  Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma.

Authors:  R D Gascoyne; S A Adomat; S Krajewski; M Krajewska; D E Horsman; A W Tolcher; S E O'Reilly; P Hoskins; A J Coldman; J C Reed; J M Connors
Journal:  Blood       Date:  1997-07-01       Impact factor: 22.113

Review 2.  TGF-beta and cancer.

Authors:  M Reiss
Journal:  Microbes Infect       Date:  1999-12       Impact factor: 2.700

3.  Frameshift mutations at mononucleotide repeats in caspase-5 and other target genes in endometrial and gastrointestinal cancer of the microsatellite mutator phenotype.

Authors:  S Schwartz; H Yamamoto; M Navarro; M Maestro; J Reventós; M Perucho
Journal:  Cancer Res       Date:  1999-06-15       Impact factor: 12.701

4.  MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers.

Authors:  S B Simpkins; T Bocker; E M Swisher; D G Mutch; D J Gersell; A J Kovatich; J P Palazzo; R Fishel; P J Goodfellow
Journal:  Hum Mol Genet       Date:  1999-04       Impact factor: 6.150

5.  Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype.

Authors:  N Rampino; H Yamamoto; Y Ionov; Y Li; H Sawai; J C Reed; M Perucho
Journal:  Science       Date:  1997-02-14       Impact factor: 47.728

6.  Frameshift somatic mutations in gastrointestinal cancer of the microsatellite mutator phenotype.

Authors:  H Yamamoto; H Sawai; M Perucho
Journal:  Cancer Res       Date:  1997-10-01       Impact factor: 12.701

7.  Clinical implications of stem cell gene Oct-4 expression in breast cancer.

Authors:  Cai-gang Liu; Ying Lu; Bin-bin Wang; Yan-jun Zhang; Rui-shan Zhang; Yang Lu; Bo Chen; Huimian Xu; Feng Jin; Ping Lu
Journal:  Ann Surg       Date:  2011-06       Impact factor: 12.969

8.  Transforming growth factor-beta regulates normal human pre-B cell differentiation.

Authors:  J A Rehmann; T W LeBien
Journal:  Int Immunol       Date:  1994-02       Impact factor: 4.823

9.  Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes.

Authors:  J H Kehrl; A B Roberts; L M Wakefield; S Jakowlew; M B Sporn; A S Fauci
Journal:  J Immunol       Date:  1986-12-15       Impact factor: 5.422

10.  Transforming growth factor-beta is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation.

Authors:  S M Wahl; D A Hunt; H L Wong; S Dougherty; N McCartney-Francis; L M Wahl; L Ellingsworth; J A Schmidt; G Hall; A B Roberts
Journal:  J Immunol       Date:  1988-05-01       Impact factor: 5.422
View more
  3 in total

1.  CD109, a negative regulator of TGF-β signaling, is a putative risk marker in diffuse large B-cell lymphoma.

Authors:  Maki Yokoyama; Masaaki Ichinoe; Sosei Okina; Yasutaka Sakurai; Norihiro Nakada; Nobuyuki Yanagisawa; Shi-Xu Jiang; Yoshiko Numata; Atsuko Umezawa; Koji Miyazaki; Masaaki Higashihara; Yoshiki Murakumo
Journal:  Int J Hematol       Date:  2016-12-28       Impact factor: 2.490

Review 2.  The Dynamic Roles of TGF-β Signalling in EBV-Associated Cancers.

Authors:  Sharmila Velapasamy; Christopher W Dawson; Lawrence S Young; Ian C Paterson; Lee Fah Yap
Journal:  Cancers (Basel)       Date:  2018-07-27       Impact factor: 6.639

Review 3.  Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy.

Authors:  Marie de Charette; Roch Houot
Journal:  Haematologica       Date:  2018-07-13       Impact factor: 9.941
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.